Eisai Co Ltd - Company Profile
Powered by
All the data and insights you need on Eisai Co Ltd in one report.
- Save hours of research time and resources with
our up-to-date Eisai Co Ltd Strategy Report
- Understand Eisai Co Ltd position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Eisai Co Ltd (Eisai) is a pharmaceutical company that discovers, develops, manufactures and markets pharmaceuticals, including prescription medicines, OTC drugs and generics. The company’s franchise areas in research include neurology and oncology. Eisai’s major products include Pariet/AcipHex, a proton pump inhibitor; Aricept, an anti-Alzheimer agent; perampanel, Halaven, an anti-cancer agent; Fycompa tablets for the treatment of epilepsy and peripheral neuropathy. Eisai has production plants in Japan, the UK, China, and India and laboratories in Japan, the US and the UK; operations in the Americas, Asia and Latin America, EMEA and Oceania with overseas sales offices in the US, Germany, France, China and South Korea. Eisai is headquartered in Tokyo, Japan.
Eisai Co Ltd premium industry data and analytics
Products and Services
Products | Brands |
---|---|
- | - |
Pariet (proton-pump inhibitor) | Aricept |
Aricept - Alzheimer's Disease/Dementia with Lewy Bodies | Iomeron |
XYZ | XYZ |
XYZ | XYZ |
XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
Year | Event | Description |
---|---|---|
2024 | New Products/Services | In April, Eisai Korea introduced Cogmate, a tool-based brain health measurement tool. |
2024 | Contracts/Agreements | In April, the company entered into an agreement with BioArctic to conduct a research evaluation focused on BAN2802. |
2024 | Plans/Strategy | In March, Eisai Inc announced its plans to invest up to US$15 million in C2N Diagnostics LLC. |
Competitor Comparison
Key Parameters | Eisai Co Ltd | Takeda Pharmaceutical Co Ltd | Astellas Pharma Inc | Chugai Pharmaceutical Co Ltd | Ono Pharmaceutical Co Ltd |
---|---|---|---|---|---|
Headquarters | Japan | Japan | Japan | Japan | Japan |
City | Bunkyo-Ku | Chuo-Ku | Chuo-Ku | Chuo-Ku | Osaka-Shi |
State/Province | Tokyo | Tokyo | Tokyo | Tokyo | Osaka |
No. of Employees | 11,076 | 49,095 | 14,484 | 7,604 | 3,761 |
Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
Name | Position | Board | Since | Age |
---|---|---|---|---|
Yasuhiko Katoh | Chairman | Executive Board | 2018 | - |
Haruo Naito | Representative Corporate Officer; Director; Chief Executive Officer | Executive Board | 2014 | - |
Ivan Cheung | Officer- Global Alzheimer's Disease; Chief Executive Officer - Eisai Inc; President - Americas Region; Chairman - Eisai Inc; Senior Vice President | Executive Board | - | - |
Gary Hendler | Senior Vice President; President - EMEA Region; Chief Executive Officer - Eisai Europe Ltd; Chairman - Eisai Europe Ltd | Executive Board | - | - |
Tatsuyuki Yasuno | Chairman - Eisai Inc; Chief Executive Officer - Eisai Inc; Senior Vice President; President - Americas Region | Executive Board | 2023 | - |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer